TNF inhibitor | 41 (25.5%) | 120 (74.5%) | 161 (100.0%) | 17 (28.8%) | 42 (71.2%) | 59 (100.0%) |
Other mode of action | 6 (18.2%) | 27 (81.8%) | 33 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Total | 47 (24.2%) | 147 (75.8%) | 194 (100.0%) | 17 (28.8%) | 42 (71.2%) | 59 (100.0%) |
Second bDMARD Retention Probability at: |
6 Months | 64.68% (3.45%) | 96.15% (2.67%) |
12 Months | 50.54% (3.61%) | 88.05% (4.59%) |
24 Months | 39.77% (3.59%) | 85.84% (4.97%) |
60 Months | 22.26% (3.53%) | 72.44% (6.95%) |
96 Months | 13.22% (3.62%) | 72.44% (6.95%) |
Biologic Retention Time (years) |
Mean, mean (SE) | 2.71 (0.25) | 6.73 (0.46) |
Lower Quartile, (95% CI) | 0.36 (0.28–0.44) | 4.18 (1.51–8.48) |
Median, (95% CI) | 1.08 (0.71–1.60) | – (8.42 –) |
Upper Quartile, (95% CI) | 4.26 (3.25–6.64) | – (–) |